SecBot SecBot
15-12G ·Filed May 26, 2026

APLS

Apellis Pharmaceuticals, Inc.
NEUTRAL
Impact 6/10
Horizonimmediate Processed5mo ago SEC0000950157-26-000636
Deregistration
Actionable Insight • Neutral

No further trading action required, APLS shares are no longer publicly traded. Monitor CVR-related events for Biogen's acquisition consideration.

DirectionNeutral
Confidencehigh
Horizonimmediate

Price Chart

Loading chart...

Executive Summary

Apellis Pharmaceuticals filed Form 15-12G to terminate its SEC registration and suspend reporting obligations, effective May 26, 2026, following the completion of Biogen's acquisition. The company's common stock was delisted via a prior 25-NSE filing, and there is now only one holder of record, reflecting the acquisition's consummation. This is a procedural step after the merger, with no further impact on public shareholders.

Key Facts

  • Form 15-12G filed to terminate registration under Section 12(g) of the Securities Exchange Act.
  • Approximate number of holders of record as of certification date: one (1).
  • Deregistration follows the completion of Biogen's acquisition (previous 25-NSE delisting on May 14, 2026).
  • Common stock will cease SEC reporting obligations effective immediately.

Financial Impact

Shareholders received $41.00 per share plus contingent value rights (CVRs) from the Biogen acquisition; no new financial impact from this filing.

Risk Factors

  • CVR value may fluctuate based on Apellis' clinical and regulatory outcomes under Biogen.
  • Future litigation or liabilities may arise post-deregistration with limited public disclosure.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
30% bullish (27 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
15-12G Filing (Primary)0000950157-26-000636
Document: 0000950157-26-000636-index-headers.html0000950157-26-000636
Document: 0000950157-26-000636-index.html0000950157-26-000636
Document: 0000950157-26-000636.txt0000950157-26-000636

Track record

5 reports on APLS

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. May 26, 202624w ago 15-12G Neutral 6/10 Viewing No price data
  2. May 14, 202626w ago 25-NSE Neutral 2/10 Entry $41.03 to $41.03 · 0.00% +1.23% vs SPY
  3. May 14, 202626w ago 8-K Bullish 8/10 Entry $41.03 to $41.03 · 0.00% +1.23% vs SPY
  4. May 4, 202628w ago 8-K Neutral 2/10 Entry $40.97 to $40.97 · 0.00% −0.80% vs SPY
  5. Mar 27, 202633w ago Institutional Cluster Mixed 6/10 Entry $16.97 to $17.09 ▲ +0.71% +1.06% vs SPY
Showing 5 of 5

US Market Status

Market Closed · Opens in 8h 57m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 26, 2026